Novartis joins Pfizer in deferring drug-price hikes

Novartis joins Pfizer in deferring drug-price hikes


Novartis on Wednesday became the second major drug company to defer price increases in 2018, citing a "dynamic environment" in the U.S. as President Trump attempts to swat away critics and use market-based pressure to bring costs down. The Swiss company follows Pfizer Inc., which recently postponed price increases from July 1 to Jan. 1, prompting Mr. Trump to take a victory lap after he personally spoke to the CEO.



from Biotech News